News

Cardio3 starts Phase III
Enlarge image

Clinical trialsBelgiumEU

Cardio3 starts Phase III

23.11.2012 - Belgian Cardio3 BioSciences has received authorisation to begin a European Phase III trial for its autologous stem cell therapy for heart failure.

The Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) Phase III trial will recruit at least 240 patients with chronic advanced symptomatic heart failure, announced the Wallonia-based company on 22 November. The prospective, double-blinded study will compare a treatment with Cardio3’s lead product C3BS-CQR-1 to a sham treatment. The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at 9 months post-procedure. 

“We believe C3BS-CQR-1 has the potential to become an alternative to heart transplantat, which is the only curative treatment for heart failure available today“, stated Christian Homsy, CEO of Cardio3 BioSciences adding that – to his knowledge –  this would be the first Phase III trial ever for a regenerative therapy with this indication. "We look forward to confirming the promising results we have already seen in our Phase II study,” concluded Homsy. Cardio3 tested its treatment in Phase II between 2009 and 2010 in multiple clinical sites in Belgium, Serbia and Switzerland.

The therapy involves taking stem cells from a patient’s own bone marrow and re-programming those cells so that they go on to become heart cells. The cardiopoietic cells, are then injected back into the patient’s heart through a minimally invasive procedure using a catheter with the aim of repairing damaged tissue and improving heart function and patient clinical outcomes.

© eurobiotechnews.eu/bk

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR268.4%
  • SANTHERA (CH)65.50 CHF81.9%
  • ADDEX (CH)4.01 CHF79.0%

FLOP

  • MERCK KGAA (D)65.21 EUR-48.8%
  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-23.5%

TOP

  • SANTHERA (CH)65.50 CHF3175.0%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR315.2%

FLOP

  • CYTOS (CH)0.28 CHF-91.8%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.7%

No liability assumed, Date: 28.07.2014